Evaluation of the concomitant use of prophylactic treatments in patients with migraine under anti-calcitonin gene-related peptide therapies: The PREVENAC study.

导出 OA

翻译打印收藏纠错

作者： Ana Beatriz,Gago-Veiga ^[1] ; Noelia,Lopez-Alcaide ^[1] ; Sonia,Quintas ^[1] ; Iris,Fernández Lázaro ^[1] ; Javier,Casas-Limón ^[2] ; Carlos,Calle ^[3] ; Germán,Latorre ^[3] ; Nuria,González-García ^[4] ; Jesús,Porta-Etessam ^[4] ; Jaime,Rodriguez-Vico ^[5] ; Alex,Jaimes ^[5] ; Andrea,Gómez García ^[5] ; David,García-Azorín ^[6] ; Ángel Luis,Guerrero-Peral ^[6] ; Álvaro,Sierra ^[7] ; Alberto,Lozano Ros ^[8] ; Antonio,Sánchez-Soblechero ^[8] ; Javier,Díaz-de-Teran ^[9] ; Javier A,Membrilla ^[9] ; Cristina,Treviño ^[10] ; Alicia,Gonzalez-Martinez ^[1]

作者单位： Headache Unit, Hospital Universitario de la Princesa & Instituto de Investigación Sanitaria Princesa (IIS-Princesa), Madrid, Spain. ^[1] Headache Unit, Hospital Universitario Fundación Alcorcón, Alcorcón, Spain. ^[2] Headache Unit, Hospital de Fuenlabrada, Madrid, Spain. ^[3] Headache Unit, Hospital Clínico San Carlos, Madrid, Spain. ^[4] Headache Unit, Hospital Fundación Jiménez Díaz, Madrid, Spain. ^[5] Headache Unit, Hospital Clínico Universitario de Valladolid, Valladolid, Spain.;Department of Medicine, Universidad de Valladolid, Valladolid, Spain. ^[6] Headache Unit, Hospital Clínico Universitario de Valladolid, Valladolid, Spain. ^[7] Headache Unit, Hospital Universitario Gregorio Marañón, Madrid, Spain. ^[8] Headache Unit, Hospital Severo Ochoa, Madrid, Spain. ^[9] Headache Unit, Hospital Clínico Universitario de la Paz, Madrid, Spain. ^[10]

关键词 CGRP effectiveness migraine oral prophylactics response